FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> GlaxoSmithKline | AstraZeneca | lawsuit

Drugmakers cut deals in price-inflation suit

Tools

Remember the legal wrangle over the price of cancer drugs? The lawsuit pitted insurers, patients, attorneys general--perhaps even a few kitchen sinks--against 30 drug companies, including GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca, Schering Plough. At issue: Whether the companies artificially inflated drug prices, then sold the drugs to doctors at a discount, giving doctors the spread--and themselves an unfair advantage over competitors who weren't playing the game (though with so many companies allegedly involved, who wasn't?).

The latest? GlaxoSmithKline settled for $70 million, and Bristol-Myers and AstraZeneca are cutting deals. In June, a judge found Bristol-Myers, AstraZeneca and Schering-Plough liable for the price inflation. No word yet on whether Schering-Plough is also negotiating a settlement.

- read this item from The Wall Street Journal

More stories about GlaxoSmithKline   AstraZeneca   lawsuit  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.